{
  "index": 223,
  "timestamp": "2024-11-11 23:01:09",
  "original_text": "For Immediate Release: May 29, 2020 Espa√±ol The U.S. Food and Drug Administration today granted approval to Oriahnn (an estrogen and progestin combination product consisting of elagolix, estradiol and...",
  "qa_pairs": [
    {
      "text_input": "What is the purpose of Oriahnn?",
      "output": "Oriahnn is a medication used to manage heavy menstrual bleeding caused by uterine fibroids in premenopausal women.",
      "index": 223,
      "timestamp": "2024-11-11 23:01:09"
    },
    {
      "text_input": "What are the most common side effects of Oriahnn?",
      "output": "The most common side effects of Oriahnn are hot flushes, headache, fatigue and irregular vaginal bleeding.",
      "index": 223,
      "timestamp": "2024-11-11 23:01:09"
    },
    {
      "text_input": "Who should not take Oriahnn?",
      "output": "Oriahnn should not be taken by women with a history of or current blood clots, women at increased risk for blood clots, women with osteoporosis, women with a history of or current breast cancer or other hormonally-sensitive cancer, women with liver disease or undiagnosed abnormal uterine bleeding.",
      "index": 223,
      "timestamp": "2024-11-11 23:01:09"
    }
  ]
}